University of Orléans / Université d'Orléans

MINUTE-TIMESCALE > 100 MeV gamma-RAY VARIABILITY DURING THE GIANT OUTBURST OF QUASAR 3C 279 OBSERVED BY FERMI-LAT IN 2015 JUNE (2016) Uchiyama Y, Sikora M, Nalewajko K, Ohsugi T, Maldera S, Negro M, La Mura G, et al. Journal article, Original article FERMI-LAT OBSERVATIONS OF THE LIGO EVENT GW150914 (2016) Ackermann M, Ajello M, Albert A, Anderson B, Arimoto M, Atwood WB, Axelsson M, et al. Journal article, Original article THE FIRST FERMI LAT SUPERNOVA REMNANT CATALOG (2016) Acero F, Ackermann M, Ajello M, Baldini L, Ballet J, Barbiellini G, Bastieri D, et al. Journal article A large light-mass component of cosmic rays at 10(17)-10(17.5) electronvolts from radio observations (2016) Buitink S, Corstanje A, Falcke H, Hörandel JR, Huege T, Nelles A, Rachen JP, et al. Journal article Imaging Jupiter's radiation belts down to 127 MHz with LOFAR (2016) Girard JN, Zarka P, Tasse C, Hess S, De Paters I, Santos-Costa D, Nenon Q, et al. Journal article Wide-band, low-frequency pulse profiles of 100 radio pulsars with LOFAR (2016) Pilia M, Hessels JW, Stappers BW, Kondratiev VI, Kramer M, Van Leeuwen J, Weltevrede P, et al. Journal article Long-Term (156-Week) Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pooled Safety Analysis of 3 Phase III, Randomized, Controlled Trials (2016) Mease PJ, Gladman DD, Gomez-Reino JJ, Hall S, Kavanaugh A, Lespessailles E, Schett G, et al. Conference contribution Apremilast Treatment and Long-Term (156-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Pooled Analysis of a Large Database of 3 Phase III, Randomized, Controlled Trials (2016) Gladman DD, Kavanaugh A, Gomez-Reino JJ, Wollenhaupt J, Cutolo M, Schett G, Lespessailles E, et al. Conference contribution APREMILAST, AN ORAL PHOSPHODIESTERASE-4 INHIBITOR, IS ASSOCIATED WITH LONG-TERM (104-WEEK) IMPROVEMENTS IN ENTHESITIS AND DACTYLITIS IN PATIENTS WITH PSORIATIC ARTHRITIS: POOLED RESULTS FROM THREE PHASE III RANDOMIZED CONTROLLED TRIALS (2016) Gladman DD, Kavanaugh A, Adebajo AO, Gomez-Reino JJ, Wollenhaupt J, Cutolo M, Schett G, et al. Conference contribution Apremilast, an Oral Phosphodiesterase 4 Inhibitor, is Associated with Long-term (104-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Pooled Results from Three Phase III, Randomized, Controlled Trials (2016) Gladman D, Kavanaugh A, Adebajo A, Gomez-Reino J, Wollenhaupt J, Cutolo M, Schett G, et al. Conference contribution